FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
On 9 July, the FDA issued a Warning Letter to a Korean manufacturer registered as a manufacturer of over-the-counter drugs. With the Warning Letter, the FDA is responding to the documents it received from this manufacturer in response to two requests in 2022 and 2024. Since the methods, facilities or controls described in the company's response for the manufacture, processing, packaging or storage of drugs do not comply with CGMP, they are automatically considered adulterated and non-compliant.
Content
The Warning Letter lists a number of violations:
1. Lack of an adequate and written testing programme to assess stability properties. Only 3 months of data were available, with a shelf life of 2 years. There was therefore a lack of sufficient chemical and microbiological tests and data. This meant that there was no proof of compliance with the defined specifications and quality over the shelf life period.
2. The raw materials used had not been sufficiently tested with regard to identity and conformity, e.g. purity, starch and quality. This also included the error frequently identified in recent months that the batches of glycerine used were not tested for the limit values of diethylene glycol (DEG) and ethylene glycol. The FDA points this out again in its Warning Letter:
"The use of glycerin contaminated with DEG and EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https://www.fda.gov/media/167974/download.."
Conclusion
Since the company could not demonstrate that adequate testing of the manufactured products and starting materials was performed, e.g., the certificates of analysis you submitted for dermaFIT Athlete Muscle Maintenance Cream did not include adequate assay testing for active ingredient content or microbiological testing.
Accordingly, the FDA recommends that a GMP consultant be consulted and advises that the FDA may withhold approval of new applications or supplements until all violations are fully corrected and compliance with CGMP is confirmed.
Otherwise, the FDA may deny entry into the United States of articles manufactured at reBom Co., Ltd. in Sejong, South Korea.
Further details can be found directly in the Warning Letter on the FDA website.
Related GMP News
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections
19.03.2025ICMRA publishes Hybrid Inspection Pilot Summary Report
19.03.2025From Burkholderia to Ethylene Glycol - a List of Deficiencies at a Manufacturer of OTC Products
19.03.2025Warning Letter - Deficiencies in the Control of Raw and Starting Materials
19.03.2025Inadequate Microbiological Testing of Nonsterile Products - FDA Warning Letter
19.02.2025MRA on GMP Inspections between Switzerland and Canada extended